Biohaven Pharma
About Biohaven Pharma
173 articles with Biohaven Pharma
-
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
6/8/2021
A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals ringing the opening bell, June 8, 2021.
-
Biohaven Showcases 19 Presentations at the 2021 Virtual Annual Scientific Meeting of the American Headache Society
6/3/2021
- Nurtec ODT now the first and only medication for both acute and preventive treatment - New and encore clinical data presentations highlight the efficacy and safety of Nurtec ODT as both acute treatment of migraine and preventive treatment of episodic migraine
-
A platform trial is also efficient in that it enables the investigators to share placebo information.
-
Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
5/14/2021
Biohaven Pharmaceuticals announced that Nurtec® ODT will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program.
-
National Headache Foundation Survey Shows Majority of People with Migraine are Unable to Control Disease and Dissatisfied with Current Preventive Treatment Options
5/11/2021
The National Headache Foundation announced findings from a new survey, Preventing Migraine Attacks: A Current Perspective, which characterizes the experiences of people living with migraine and highlights the physical and emotional barriers to preventive treatment.
-
Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
5/10/2021
- Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020
-
Biohaven to Report First Quarter 2021 Financial Results and Recent Business Developments on May 10, 2021
4/28/2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming first quarter 2021 earnings call and webcast, reporting financial results
-
AAN Annual Meeting Highlights: Sleep Quality, Migraine, COVID-19 Interferon Treatment and More
4/21/2021
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them. -
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
4/13/2021
- Pivotal trial of rimegepant for the preventive treatment of migraine spotlights reduction of 4.3 monthly migraine days during weeks 9-12 and rapid onset of preventive effects observed within the first week of treatment - Post-hoc analysis of rimegepant in the acute treatment of migraine dosed on an as needed (p.r.n.) basis demonstrated clinically relevant reductions in monthly migraine days over time
-
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
4/7/2021
- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021 - Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020
-
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
3/29/2021
-- Zavegepant is a high affinity, selective and structurally unique, third generation, CGRP receptor antagonist in development for both migraine and non-migraine CGRP-mediated diseases -- Biohaven and Royalty Pharma have previously announced a funding agreement to advance the clinical development of intranasal and oral formulations of zavegepant
-
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Mar 16, 2021
3/16/2021
Biohaven Pharmaceutical Holding Company Ltd., a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.
-
Biohaven Announces Proposed Public Offering Of Common Shares - Mar 15, 2021
3/15/2021
Biohaven Pharmaceutical Holding Company Ltd., a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, announced that it has commenced an underwritten public offering of $200 million of its common shares.
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine
3/11/2021
- NURTEC ODT obtained market authorization in the United Arab Emirates, along with the recent approval in Israel - NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT)
-
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital
3/10/2021
Biohaven's verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH
-
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
3/1/2021
Biohaven reports NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers
-
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
2/22/2021
-Biohaven's proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19 -BHV-1200, a COVID-19 targeting MATE compound, recently completed in vitro testing that demonstrated activity against SARS-CoV-2 wild-type as well as mutants associated with reduced susceptibility to therapeutic monoclonal antibodies and emerging strains
-
Biohaven Provides Update On ESG Practices
2/8/2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the advancement of several important steps that underscore the company's commitment to sound Environmental, Social and Governance ("ESG")
-
Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT
1/25/2021
Biohaven Pharmaceutical Holding Company Ltd.today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2020.